Literature DB >> 387488

Metformin: a review of its pharmacological properties and therapeutic use.

L S Hermann.   

Abstract

In a survey, the pharmacological and clinical documentation of metformin is presented and discussed, and the present state of knowledge relating to metformin-associated lactic acidosis is reviewed. The use of metformin in the treatment of diabetes is based on clinical experience over twenty years. It has been well documented that metformin is effective in maturity-onset diabetes both as monotherapy and in combination with a sulphonylurea. An advantage of metformin treatment is the tendency to weight reduction and the absence of significant hypoglycaemia; blood glucose levels are reduced only to normal. The disadvantages are the gastro-intestinal side effects and the potential risk of vitamin B 12 and folic acid deficiency during long-term use. Metformin-associated lactic acidosis is a very rare complication, which has mainly occured in patients with serious renal insufficiency or other contra-indications to the use of metformin. The association between phenformin and lactic acidosis has led to withdrawal of this biguanide in several countries. Metformin differs from phenformin in certain important respects, and the normal use of metformin does not involve the risk of side effects disproportionate to the intended effect. Further experimental studies are required to substantiate pharmacokinetics and metabolic effects of metformin in man.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 387488

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  48 in total

1.  Metformin: historical overview.

Authors:  Clifford J Bailey
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 2.  [Value of biguanide in therapy of diabetes mellitus].

Authors:  E Haupt; U Panten
Journal:  Med Klin (Munich)       Date:  1997-08-15

3.  Effects of insulin, biguanide antihyperglycaemic agents and beta-adrenergic agonists on pathways of myocardial proteolysis.

Authors:  D P Thorne; T D Lockwood
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

4.  Metformin enhances certain insulin actions in cultured rat hepatoma cells.

Authors:  F Purrello; D Gullo; M Buscema; V Pezzino; R Vigneri; I D Goldfine
Journal:  Diabetologia       Date:  1988-06       Impact factor: 10.122

5.  Heeding clues to metformin-associated lactic acidosis: prompt response can save life.

Authors:  U Kumar; B Chennavir; A Gopi
Journal:  BMJ Case Rep       Date:  2009-05-10

6.  Metformin monitoring..

Authors:  P Biron
Journal:  Can Fam Physician       Date:  1980-05       Impact factor: 3.275

Review 7.  Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer.

Authors:  Darren Micallef; Sarah Micallef; Pierre Schembri-Wismayer; Jean Calleja-Agius
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-12-01

8.  Role of AMP-activated protein kinase in mechanism of metformin action.

Authors:  G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

9.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

Authors:  Yan Shu; Steven A Sheardown; Chaline Brown; Ryan P Owen; Shuzhong Zhang; Richard A Castro; Alexandra G Ianculescu; Lin Yue; Joan C Lo; Esteban G Burchard; Claire M Brett; Kathleen M Giacomini
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.